600422 KPC Pharmaceuticals, Inc.
- 22.19
- +0.59+2.73%
KPC Pharmaceuticals, Inc. News
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has
Kunming Pharmaceutical Group (600422): Local fine-tuning is expected to be lower and higher throughout the year
Kunming Pharmaceutical Group (600422): Steady improvement in business quality, non-growth in line with expectations
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the thre
Kunming Pharmaceutical Group (600422): The “Kunming Traditional Chinese Medicine 1381” brand achieved initial results, and the three major gold products performed brilliantly
Kunming Pharmaceutical Group (600422) Company Review Report: Short-term pressure on Q1 performance, Kunming Traditional Chinese Medicine accelerates growth
Kunming Pharmaceutical Group (600422): Yinfa Health Industry Leader Sets Sail Again in Strategic Reshaping
Kunming Pharmaceutical Group (600422): Doubling the industrial revenue target by the end of 2028 lays the foundation for medium- to long-term high growth
Kunming Pharmaceutical Group (600422): Smooth integration strategy clearly released five-year plan to guide growth
Kunming Pharmaceutical Group (600422): Reform and reshaping, the profit side growth rate is impressive
Kunming Pharmaceutical Group (600422): Yinfa Industry Strategy Leads Deep Cultivation of Premium Sinopharm and the Sanqi Industrial Chain
Kunming Pharmaceutical Group (600422) 2023 Annual Report Review Report: Continued Integration into China Resources 39 Company Releases Five-Year Strategic Plan
Kunming Pharmaceutical Group (600422) Company Information Update Report: Results of cost reduction and efficiency are beginning to show, the five-year plan is clear and firm
Kunming Pharmaceutical Group (600422): Good performance in the injection business, efforts in sorting out the three major divisions
Review of the 2023 report of KPC Group (600422): The results of integration were clearly released, and the five-year “strategic plan” entered a new chapter of development
Kunming Pharmaceutical Group (600422): Released a five-year strategic development plan. Future highlights are “inventory integration” and “incremental expansion”
Kunming Pharmaceutical Group (600422): Significant increase in the company's profitability, focusing on the Yinfa economic market
KPC Group (600422): Consolidate the foundation and go to battle lightly
Kunming Pharmaceutical Group (600422): Integrating Progressive Marketing Changes to Empower Growth
Kunming Pharmaceutical Group (600422): Quality Chinese medicines and chronic disease management focus on the first stock in the Yinfa economy
Analysis
Price Target
No Data
